<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505879</url>
  </required_header>
  <id_info>
    <org_study_id>1205731-1</org_study_id>
    <nct_id>NCT03505879</nct_id>
  </id_info>
  <brief_title>Next Generation Sequencing Detection of Lyme Disease</brief_title>
  <official_title>Next Generation Sequencing to Detect Borrelia Burgdorferi DNA in the Blood of Pediatric Patients With Lyme Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karius, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Next Generation Sequencing is capable of sequencing millions of small strands of DNA from a
      single blood sample, potentially improving its sensitivity compared to PCR testing, which
      only detects predetermined larger strands of DNA. We will test the ability of NGS to detect
      Borrelia burgdorferi DNA in the blood of pediatric patients with Lyme disease. We will
      conduct an observational study of NGS testing on pediatric patients at all stages of Lyme
      disease. Study involvement will require a single study visit for clinical data collection and
      blood draw. We will enroll patients at all phases of suspected Lyme disease, collect
      clinically relevant information, and test for Lyme disease using Next Generation Sequencing
      and standard Lyme serologic testing. If the patient has multiple erythema migrans, Lyme
      meningitis, facial nerve palsy, arthritis, or carditis, a B. burgdorferi serum PCR will also
      be sent. Enrollment and Next Generation Sequencing blood draw will occur before or up to 24
      hours after the first dose of antibiotics is administered. We will also study the impact of
      antibiotics on NGS testing by running the test 6-24 hours after antibiotics are started among
      a small subset of patients with a multiple erythema migrans rash. Collected data will be
      analyzed with basic descriptive statistics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of Next Generation Sequencing to detect Borrelia burgdorferi DNA in blood</measure>
    <time_frame>1 year</time_frame>
    <description>To determine if Next Generation Sequencing (NGS) is able to detect Borrelia burgdorferi DNA in the blood of pediatric patients with Lyme disease, including those with erythema migrans (single or multiple), Lyme meningitis, Lyme carditis, Lyme disease facial palsy, and Lyme arthritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NGS detection of Borrelia burgdorferi DNA following antibiotics</measure>
    <time_frame>1 year</time_frame>
    <description>To determine if Next Generation Sequencing (NGS) is able to detect Borrelia burgdorferi DNA in the blood of pediatric patients with a multiple erythema migrans rash shortly after the first dose of antibiotics.</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lyme Disease</condition>
  <condition>Pediatric Infectious Disease</condition>
  <condition>Erythema Migrans</condition>
  <condition>Lyme Arthritis</condition>
  <condition>Lyme Carditis</condition>
  <condition>Lyme Disease Meningitis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples for detection of infectious pathogens by next generation sequencing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cases will include pediatric patients age 1 to &lt;18 years old who currently have a specific
        Lyme disease syndrome and have been on antibiotics for less than 24 hours prior to blood
        draw
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Lyme disease subjects (Cases):

        Inclusion criteria:

          1. Age 1 to &lt;18 years old

          2. The subject has spent time in a Lyme-endemic area during the previous month

          3. The subject has a suspected Lyme disease infection

        Exclusion criteria:

          1. Past infection with Lyme disease

          2. Received oral or IV antibiotics within 1 month prior to presentation Note: Subjects
             may be enrolled if NGS blood test can be drawn &lt;24 hours after the first dose of Lyme
             diseasetargeted antibiotics is administered
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christy Beneri, DO</last_name>
    <phone>(631) 444-7692</phone>
    <email>Christy.Beneri@stonybrookmedicine.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Handel, MD</last_name>
    <phone>(631) 444-7692</phone>
    <email>Andrew.handel@stonybrookmedicine.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Setauket</city>
        <state>New York</state>
        <zip>11733-9219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Mattias</last_name>
      <phone>631-444-6900</phone>
      <email>wendy.mattias@stonybrookmedicine.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Infanzon</last_name>
      <phone>631-444-8832</phone>
      <email>erin.infanzon@stonybrookmedicine.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christy A Beneri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Handel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme Disease - United States, 2008-2015. MMWR Surveill Summ. 2017 Nov 10;66(22):1-12. doi: 10.15585/mmwr.ss6622a1.</citation>
    <PMID>29120995</PMID>
  </reference>
  <reference>
    <citation>Theel ES. The Past, Present, and (Possible) Future of Serologic Testing for Lyme Disease. J Clin Microbiol. 2016 May;54(5):1191-6. doi: 10.1128/JCM.03394-15. Epub 2016 Feb 10. Review.</citation>
    <PMID>26865690</PMID>
  </reference>
  <reference>
    <citation>Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of lyme borreliosis. Clin Microbiol Rev. 2005 Jul;18(3):484-509. Review.</citation>
    <PMID>16020686</PMID>
  </reference>
  <reference>
    <citation>Babady NE, Sloan LM, Vetter EA, Patel R, Binnicker MJ. Percent positive rate of Lyme real-time polymerase chain reaction in blood, cerebrospinal fluid, synovial fluid, and tissue. Diagn Microbiol Infect Dis. 2008 Dec;62(4):464-6. doi: 10.1016/j.diagmicrobio.2008.08.016. Epub 2008 Oct 22.</citation>
    <PMID>18947959</PMID>
  </reference>
  <reference>
    <citation>Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis. 2001 Sep 15;33(6):780-5. Epub 2001 Aug 10.</citation>
    <PMID>11512082</PMID>
  </reference>
  <reference>
    <citation>da Fonseca AJ, Galv√£o RS, Miranda AE, Ferreira LC, Chen Z. Comparison of three human papillomavirus DNA detection methods: Next generation sequencing, multiplex-PCR and nested-PCR followed by Sanger based sequencing. J Med Virol. 2016 May;88(5):888-94. doi: 10.1002/jmv.24413. Epub 2015 Nov 6.</citation>
    <PMID>26496186</PMID>
  </reference>
  <reference>
    <citation>Abril MK, Barnett AS, Wegermann K, Fountain E, Strand A, Heyman BM, Blough BA, Swaminathan AC, Sharma-Kuinkel B, Ruffin F, Alexander BD, McCall CM, Costa SF, Arcasoy MO, Hong DK, Blauwkamp TA, Kertesz M, Fowler VG Jr, Kraft BD. Diagnosis of Capnocytophaga canimorsus Sepsis by Whole-Genome Next-Generation Sequencing. Open Forum Infect Dis. 2016 Jul 12;3(3):ofw144. eCollection 2016 Sep.</citation>
    <PMID>27704003</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stony Brook University</investigator_affiliation>
    <investigator_full_name>Christy Beneri</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Next Generation Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Erythema Chronicum Migrans</mesh_term>
    <mesh_term>Glossitis, Benign Migratory</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

